File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1371/journal.pone.0223301
- Scopus: eid_2-s2.0-85073596548
- PMID: 31626655
- WOS: WOS:000532567700011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: An alternative approach for estimating the number needed to treat for survival endpoints
Title | An alternative approach for estimating the number needed to treat for survival endpoints |
---|---|
Authors | |
Keywords | Radical prostatectomy Cancer treatment Randomized controlled trials Platelets Medical risk factors |
Issue Date | 2019 |
Publisher | Public Library of Science. The Journal's web site is located at http://www.plosone.org/home.action |
Citation | PLoS One, 2019, v. 14 n. 10, p. article no. e0223301 How to Cite? |
Abstract | To investigate the issues of the NNT based on the absolute risk reduction (ARR), namely NNTARR; and to propose an alternative definition and an estimation procedure based on the restricted mean survival time (RMST), namely NNTRMST, for RCTs. Three recent clinical trials with survival endpoints, representing different scenarios, were selected to compare the performance of the NNTARR and NNTRMST. For each trial, both versions of NNT were estimated using the reconstructed individual-level data, and the average life gain (ALG) was derived to show the differences between the NNTARR and NNTRMST. Four hypothetical scenarios were constructed to further explore the advantages and disadvantages of each definition of the NNT for survival endpoints. For the illustrative trial examples, the NNTARR failed to capture the profile of the treatment effect over time as it is calculated at a specific time point. Sometimes it may even result in misinterpretations of the treatment benefit. In particular, when either the observed event rates are low, the two survival curves cross, or a mixture of survival patterns exist. In contrast, the NNTRMST based on the average survival (or event-free) time can quantify the treatment effect more accurately and its interpretation is more intuitive and clinically meaningful. The NNTRMST can be used as an alternative measure for quantifying treatment effect in RCTs, especially so in the case of the ALG, which helps practitioners to better understand the magnitude of the benefit conferred by treatment. |
Persistent Identifier | http://hdl.handle.net/10722/287726 |
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 0.839 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | YANG, Z | - |
dc.contributor.author | Yin, G | - |
dc.date.accessioned | 2020-10-05T12:02:22Z | - |
dc.date.available | 2020-10-05T12:02:22Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | PLoS One, 2019, v. 14 n. 10, p. article no. e0223301 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/10722/287726 | - |
dc.description.abstract | To investigate the issues of the NNT based on the absolute risk reduction (ARR), namely NNTARR; and to propose an alternative definition and an estimation procedure based on the restricted mean survival time (RMST), namely NNTRMST, for RCTs. Three recent clinical trials with survival endpoints, representing different scenarios, were selected to compare the performance of the NNTARR and NNTRMST. For each trial, both versions of NNT were estimated using the reconstructed individual-level data, and the average life gain (ALG) was derived to show the differences between the NNTARR and NNTRMST. Four hypothetical scenarios were constructed to further explore the advantages and disadvantages of each definition of the NNT for survival endpoints. For the illustrative trial examples, the NNTARR failed to capture the profile of the treatment effect over time as it is calculated at a specific time point. Sometimes it may even result in misinterpretations of the treatment benefit. In particular, when either the observed event rates are low, the two survival curves cross, or a mixture of survival patterns exist. In contrast, the NNTRMST based on the average survival (or event-free) time can quantify the treatment effect more accurately and its interpretation is more intuitive and clinically meaningful. The NNTRMST can be used as an alternative measure for quantifying treatment effect in RCTs, especially so in the case of the ALG, which helps practitioners to better understand the magnitude of the benefit conferred by treatment. | - |
dc.language | eng | - |
dc.publisher | Public Library of Science. The Journal's web site is located at http://www.plosone.org/home.action | - |
dc.relation.ispartof | PLoS ONE | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Radical prostatectomy | - |
dc.subject | Cancer treatment | - |
dc.subject | Randomized controlled trials | - |
dc.subject | Platelets | - |
dc.subject | Medical risk factors | - |
dc.title | An alternative approach for estimating the number needed to treat for survival endpoints | - |
dc.type | Article | - |
dc.identifier.email | Yin, G: gyin@hku.hk | - |
dc.identifier.authority | Yin, G=rp00831 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1371/journal.pone.0223301 | - |
dc.identifier.pmid | 31626655 | - |
dc.identifier.pmcid | PMC6799908 | - |
dc.identifier.scopus | eid_2-s2.0-85073596548 | - |
dc.identifier.hkuros | 315653 | - |
dc.identifier.volume | 14 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | article no. e0223301 | - |
dc.identifier.epage | article no. e0223301 | - |
dc.identifier.isi | WOS:000532567700011 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1932-6203 | - |